Podcasts about Genetic testing

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this enlightening episode, Kashif Khan, co-founder of The DNA Company, discusses the intricate connection between genetics, health and wellness. Khan shares his personal health journey and explains how he went from battling multiple chronic diseases to becoming a pioneer in genetic research. He emphasizes the importance of understanding one's genetic makeup to navigate health challenges more effectively, touching on topics such as the role of the nervous system, diet, environment and the impact of ancestral genetic expressions. Beyond this, he and Gabby discuss how social connections can actually impact your health. Overall, this conversation covers actionable insights on how to tailor lifestyle choices, optimize health and manage stress based on individual genetic profiles. Check out this insightful conversation that will inspire you to dig deeper, make changes and better understand your body's individual needs.  Kashif Khan's Website: https://kashkhanofficial.com/ Follow Kashif Khan on Instagram: KashKhanOfficial For more on Gabby Instagram @GabbyReece TikTok @GabbyReeceOfficial The Gabby Reece Show Podcast on YouTube: https://www.youtube.com/@GabbyReece  The Gabby Reece Show podcast is Produced by Rainbow Creative (https://www.rainbowcreative.co/)  Thank You to Our Sponsors Timeline - My friends at Timeline are offering 20% off, just for my listeners. Head to timeline.com/gabby to get started. Ritual - Get 25% off your first month at ritual.com/GABBY Laird Superfood - High-quality ingredients paired with incredible taste. Use the code GABBY20 for 20% off your purchase at http://lairdsuperfood.com CHAPTERS 00:00 Understanding the Brain's Duality: Trauma vs. Gratitude 00:39 Introduction to the Guest: Kashif Khan 01:53 Kashif Khan's Personal Health Journey 02:47 The Role of Genetics in Health and Wellness 04:01 The Impact of Dopamine and Serotonin on Behavior 07:12 Genetic Traits and Their Influence on Health 12:00 The Importance of Sunlight and Circadian Biology 15:29 Cold and Heat Stress: Benefits and Adaptations 20:43 Longevity and Healthspan: The Role of Relationships 29:00 Genetic Testing and Personalized Health 34:29 Contrasting Personalities in the Workplace 35:10 Discovering Personal Traits and Leadership Styles 35:45 The Journey of Self-Discovery and Purpose 37:15 Applying Genetic Research to Real Life 38:40 The Gender Gap in Medical Research 40:26 Understanding Bioindividuality and Health 47:20 Genetic Testing and Personalized Healthcare 49:21 The Role of the Nervous System in Health 01:03:22 Epigenetics and Generational Trauma 01:06:32 Understanding Personal Identity and Survival Tools 01:07:39 Mapping the Mind and Discovering Self 01:08:59 Unlocking Superpowers and Managing Impulses 01:11:45 Invisible Factors Impacting Longevity 01:14:14 The Power of Real Food and Natural Remedies 01:17:56 Preventing Dementia and Alzheimer's 01:21:12 The Role of Genetics in Health and Performance 01:24:36 Empowerment Through Personalized Health 01:33:41 Balancing Health, Family, and Purpose Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast is brought to you by Nature's Bounty. With a long-standing commitment to supporting women's health and wellness, Nature's Bounty is proud to partner with Susan G. Komen in the fight to end breast cancer. As we kick off National Breast Cancer Awareness Month, with eyes and ears on the breast cancer community, we are highlighting one of our passionate Komen donors to talk about why she chooses to support Susan G. Komen. Robin Eggert Elm is a long time 3-day supporter. She first started walking with her mom and sister in 2002 and now walks yearly with an ever-growing team of family and friends. Robin has spent more than 20 years in the health care industry and has worked with more than 100 mission-driven, not-for-profit organizations, including health systems,and service providers, senior housing and Catholic women religious congregations. Robin is truly passionate about walking as long as she can to continue fighting for a cure. Today, she's here to tell us about why she chooses to partner with Komen in this fight.

Click here to send us a topic idea or question for Weekend Wisdom.Question: We very recently brought home our second child through domestic infant adoption. We feel very fortunate, and our son is developing well; we are also settling into the new routine.  We matched with our Son's birth mother through a local agency, and unfortunately, she decided that she did not want to meet us. She gave no information about the biological father.  We know she was caucasian, but honestly, it is unclear whether our son is entirely caucasian or not. The pediatrician said it was a mystery, and he may be caucasian with a darker complexion, or biracial, some amount of Hispanic, black, or any other heritage. We want to do everything in our power to be informed, acknowledge, and celebrate any ethnic background that is presented, but short of doing a DNA ancestry service on a baby that is a few weeks old, I don't really know where to begin- I'd appreciate any guidance you have. Resources:Raising a Transracial or Multicultural ChildAdoptee VoicesEthical Issues in Genetic Testing in AdoptionGenetic Testing and Genealogy for AdopteesGenetic Testing for Adoptees – Is It Worth It?Support the showPlease leave us a rating or review. This podcast is produced by www.CreatingaFamily.org. We are a national non-profit with the mission to strengthen and inspire adoptive, foster & kinship parents and the professionals who support them.Creating a Family brings you the following trauma-informed, expert-based content: Weekly podcasts Weekly articles/blog posts Resource pages on all aspects of family building

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Legendary music star Sheryl Crow shares her personal breast cancer story and how she's become a leading voice for early detection. Also, to kick off Breast Cancer Awareness Month, our TODAY team highlights the importance of genetic testing and screenings with a plaza event where hundreds sign up for free kits. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guest: Jennifer M. Kalish, MD, PhD, FAAP Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting the right tests, and addressing barriers such as insurance and interpretation. Dr. Kalish is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Director of the Beckwith-Wiedemann Syndrome Program at the Children's Hospital of Philadelphia. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.

Breast cancer affects everyone differently. African American and Black women are 40% more likely to die from breast cancer than white women. Biology and genes are driving factors, but we cannot overlook the fears and concerns women in these communities have when it comes to seeking medical care. Mistrust, bad experiences and deep-rooted bias are all standing in the way of saving more lives from breast cancer. Today, we're joined by Jessica Williams, a leading and powerful voice in the Black community in South Florida. And Gil Zepeda, the Development Manager of Susan G. Komen in Florida. Jessica and Gil just took part in an event that brough mobile mammography to an underserved neighborhood in South Florida.

What genetic tests actually do—and what they don't—so you know when to use them (and when not to). Practical next steps. Chapters below. For step-by-step guides + live Q&A, join the community: https://familybuilding.net/building-your-family-community/ You'll learn: Screening vs diagnostic: what each actually tells you Carrier testing, NIPT, and embryo testing (PGT‑A/M): when it helps vs overkill Limits: false positives/negatives, VUS, and context (why “a result” ≠ a decision) Donor gametes: brief considerations for donor sperm/egg Questions to ask your clinic + first steps this week

Michael welcomes  Dr. Sandy Rolfe, WEDI's Genomics Workgroup Chair Clinical Content Lead, InterQual, Optum Insight Lesley Berkeyheiser, WEDI's Privacy & Security Workgroup Co-Chair, Assessor with DirectTrust Thanh Thien Nguyen, WEDI's Privacy & Security Workgroup Co-Chair, Executive Director, Kaiser Permanente to discuss their workgroups working together to spotlight the intersection between direct to consumer (DTC) genetic tests and some different privacy and security issues associated with these types of tests. The two workgroups collaborated to develop a Fact Sheet to help consumers take action to protect their data, available here- https://www.wedi.org/2025/07/12/direct-to-consumer-genetic-dna-testing-actions-consumers-can-take-to-protect-their-health-data/  Current regulations and requirements Thanh Thien references in the episode HIPAA Privacy Rule- https://www.hhs.gov/hipaa/for-professionals/privacy/index.html HIPAA Security Rule- https://www.hhs.gov/hipaa/for-professionals/security/index.html Genetic Information Nondiscrimination Act of 2008- https://www.govinfo.gov/content/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf Federal Trade Commission Act- https://www.ftc.gov/legal-library/browse/statutes/federal-trade-commission-act California Consumer Privacy Act of 2018- https://oag.ca.gov/privacy/ccpa California Privacy Rights Act- https://thecpra.org/ State Privacy Law Tracker- https://iapp.org/resources/article/us-state-privacy-legislation-tracker/

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jason Silverman talk to Dr. Amber Hildreth, pediatric gastroenterologist and transplant hepatologist at Rady Children's Hospital and Assistant Professor at the University of California San Diego. She is also a clinician scientist at the Rady Children's Institute for Genomic Medicine. We discuss how genetic testing is transforming the way we care for children with rare GI and liver diseases.Learning objectivesRecognize key differences between various types of genetic testing.Discuss several applications of genetic testing in care for children with GI disorders.Understand the role of the genetic counselor in integrating genetic testing into GI practice.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

During Hispanic Heritage Month, we reflect not only on cultural pride but also on the urgent health challenges facing the Latino community. Breast cancer is the most commonly diagnosed cancer among Latinas, and yet barriers such as language, limited access to care and cultural stigma often prevent women from receiving the support they need. In this episode of Real Pink, we're joined by Dr. Laura Logie of Nueva Vida, a trusted partner of Susan G. Komen® and a member of the ShareForCures® Alliance. Together, we'll explore how culturally responsive care can transform the breast cancer experience, break down barriers and ensure that Latinas feel seen, heard and supported every step of the way.

SHOWNOTES:

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Naomi's story is a powerful reminder of how something as simple as a routine mammogram—and even a scheduling mix-up—can change the course of your life. In this conversation, she opens up about her breast cancer journey, the impact it's had on her career, her family, and her outlook on life, and why she's passionate about encouraging others to take that potentially life-saving 15 minutes to get screened.

This week, Ash is joined by Lindsey Strong, founder of Designer Genes Co, for an eye-opening conversation about the power of genetic testing, personalized health, and the rising role of peptides in modern wellness. Lindsey shares her own health journey and explains how DNA testing provides a far more complete picture than traditional blood work, uncovering everything from food sensitivities to hormonal pathways. Together, they explore how understanding genetic predispositions can transform wellness into a proactive and intentional practice rather than a reactive one. The discussion also dives into the often-overlooked roles of histamines and peptides. Lindsey explains how histamines impact not just allergies but also brain chemistry, sleep, and anxiety, particularly in the wake of COVID. She then demystifies peptides, small amino acid chains that play a key role in healing and recovery while cutting through the hype to share their real benefits and safe uses. By combining peptide therapy with DNA-based insights, Lindsey shows how listeners can embrace a holistic approach to health, reclaim energy, and create lasting balance.   In This Episode, You'll Learn: Why genetic testing reveals deeper health insights than traditional blood tests. How DNA data can guide personalized wellness plans. The surprising role histamines play in mood, sleep, and post-COVID health. What peptides are, how they work, and why media myths often miss the mark. Strategies for safely incorporating peptides into your health routine. How DNA testing and peptide therapy together create a holistic path to optimal wellness.   Visit shopify.com/youturn and only pay $1 for your first month's trial. Connect with Lindsey Strong Website: https://thedesignergenesco.com/genomics Body by Design Blueprint: https://thedesignergenesco.com/bbd Instagram: https://www.instagram.com/thedesignergenesco/   Connect with Ash: https://www.instagram.com/ashleystahl/ Want to become a professional speaker and skyrocket your personal brand?  Ashley's team at Wise Whisper Agency offers a done-with-you method to get your signature talk written and booked and it's helped more than 100 clients onto the TEDx stage! Head over to WiseWhisperAgency.com/speak  

Genetic testing is more than just ancestry results. It can be one of the most powerful tools for supporting your child's long-term health and making informed medical decisions. In this empowering episode, Dr. Elana is joined by board-certified genetic counselor, Natalie Samson, to explore how DNA testing can help personalize everything from supplements to nutrition, vaccine protocols and emotional well-being. One of the most important parts of this conversation is how genetic insights can help assess vaccine risk. You'll learn how inflammation markers, methylation, detox pathways and oxidative stress genes can influence how a child responds to vaccines. With this information, parents can feel more confident in their ability to support their child's unique biology before and after vaccines. Natalie makes complex science feel easy to understand, offering real-life examples for moms who want clarity, not confusion. Dr. Elana also shares how genetic testing helped her tailor supplement plans, prepare for pregnancy and feel more grounded in her family's health decisions. Whether you are planning for pregnancy, navigating chronic symptoms, or facing vaccine decisions, this episode offers trusted education and encouragement so you feel informed and prepared. Topics Covered In This Episode: Genetic testing for personalized health plans How epigenetics influences chronic disease risk DNA-based vaccine risk assessment and immune support Understanding detox pathways and inflammation markers How genetic insights guide nutrition and supplement choices Supporting children's emotional health through neurotransmitter genetics Show Notes: Mention this podcast episode, and you can get 15% off an appointment with Natalie Follow @goldengeneticshealth on Instagram Click here to learn more about Dr. Elana Roumell's Doctor Mom Membership, a membership designed for moms who want to be their child's number one health advocate! Click here to learn more about Steph Greunke, RD's online nutrition program and community, Postpartum Reset, an intimate private community and online roadmap for any mama (or mama-to-be) who feels stuck, alone, and depleted and wants to learn how to thrive in motherhood. Listen to today's episode on our website Natalie is a dedicated Board-Certified Genetic Counselor devoted to transforming healthcare through personalized, integrative, and preventative approaches. She established her own practice, Golden Genetics to introduce an integrative and holistic approach to genetic counseling and testing, combining it with nutrition and nutrigenomics. She focuses on cancer, neurology and nutrigenomics and she aims to provide preventative and personalized care in genetic counseling and testing. This Episode's Sponsors  Enjoy the health benefits of PaleoValley's products such as their supplements, superfood bars and meat sticks.  Receive 15% off your purchase by heading to paleovalley.com/doctormom  Discover for yourself why Needed is trusted by women's health practitioners and mamas alike to support optimal pregnancy outcomes. Try their 4 Part Complete Nutrition plan which includes a Prenatal Multi, Omega-3, Collagen Protein, and Pre/Probiotic. To get started, head to thisisneeded.com, and use code DOCTORMOM20 for 20% off Needed's Complete Plan! Active Skin Repair is a must-have for everyone to keep themselves and their families healthy and clean.  Keep a bottle in the car to spray your face after removing your mask, a bottle in your medicine cabinet to replace your toxic first aid products, and one in your outdoor pack for whatever life throws at you.  Use code DOCTORMOM to receive 20% off your order + free shipping (with $35 minimum purchase). Visit BLDGActive.com to order. INTRODUCE YOURSELF to Steph and Dr. Elana on Instagram. They can't wait to meet you! @stephgreunke @drelanaroumell Please remember that the views and ideas presented on this podcast are for informational purposes only.  All information presented on this podcast is for informational purposes and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a healthcare provider. Consult with your healthcare provider before starting any diet, supplement regimen, or to determine the appropriateness of the information shared on this podcast, or if you have any questions regarding your treatment plan.

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.---This podcast is supported by:Ferring Pharmaceuticals https://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.---TIMESTAMPS0:00 - Introduction1:48 - Active Surveillance in Low-Risk Prostate Cancer7:08 - Molecular Testing and Risk Stratification8:28 - Radiation Therapy Approaches20:16 - PSA Recurrence and PSMA PET Scans32:40 - The Role of ADT37:15 - PSMA PET Scans40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer46:54 - Treatment Intensification vs. De-Intensification Trials55:59 - Castration-Resistant Prostate Cancer

Today's guest is Tara Garst, personal trainer, flexologist, and breast cancer previvor. With a long history of breast cancer in her immediate family, Tara got genetic testing and tested positive for BRAC1 genetic mutation. Armed with this knowledge, she was able to make many decisions that were best for her due to her circumstances.We talk all about genetic testing, the power of knowledge, lifestyle choices to mitigate further risk, the support of those around you, and so much more. Not everyone understands these types of preventative measures, so this is a powerful conversation to share with others.Resources:Tara's Email: taragarst@gmail.comFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Did you know that in some families with a history of prostate cancer, the women may have an increased risk of breast cancer? People with one or more first-degree relatives (father or brother) who have had prostate cancer may have an increased risk of breast cancer, especially if the prostate cancer was diagnosed at a young age. This also works in reverse with a family history of breast cancer. This increased risk is likely due to inherited gene mutations. We are lucky to be joined today by genetic testing expert, Dr. Tuya Pal. Dr. Pal is here to discuss the importance of early detection and to decode some common questions surrounding genetic testing.

Love the episode? Send us a text!In this special episode of Breast Cancer Conversations, host Laura Carfang speaks with Dr. Troso  about the evolving role of DNA testing in breast cancer care. Together, they break down the three main types of testing:Hereditary genetic testing: Identifying inherited mutations such as BRCA1, BRCA2, and PALB2 (among others) that increase cancer risk and influence prevention and treatment decisions.Somatic (tumor) testing: Analyzing mutations within the tumor itself—such as PIK3CA or ESR1 mutations—to guide targeted therapies and manage resistance in advanced disease.Circulating tumor DNA (ctDNA) testing: Also known as a liquid biopsy, this emerging tool uses blood tests to detect cancer DNA fragments. It holds promise for monitoring recurrence, guiding treatment earlier, and advancing clinical trials.Tune into this Special! 

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, we are sharing an episode of Your Healthiest Healthy, in which our Honorary Vice Chair, Paula Schneider, made an appearance. In the episode, she discusses her cancer journey, the current landscape, and Paula's new book, Love Stays Strong, which is out today, September 2.

We are happy to welcome back the Honorary Vice Chair of Susan G. Komen, Paula Schneider, and today she is also joined by her two daughters Zoe and Chloe. Paula faced a triple-negative breast cancer diagnosis in 2007 – after losing her mother to metastatic breast cancer years before. It goes without saying that Paula's work is beyond personal. Since joining Komen in 2017, Paula has helped the organization usher in new programs, support services and policies that are helping families have a better chance of survival and a greater quality of life. This year, Paula has also published a children's book inspired by her own breast cancer experience – which drops THIS WEEK on Sept. 2nd. Love Stays Strong is a book about the strength of a family's love, especially during times of illness – designed to help parents or caregivers talk to young children about any kind of serious illness in the family.

Send us a textCould the opioid crisis be solved through genetic testing? What if doctors could identify your addiction risk before prescribing pain medication? These questions drive the innovative work at Thrive Genetics, where personalized medicine is revolutionizing how we approach pain management and addiction prevention.James Piacentino shares his journey from tech executive to healthcare innovator, motivated by watching his father struggle with alcoholism and prescription drug addiction. This deeply personal mission led him to create a system that combines genetic testing with behavioral analysis to generate comprehensive addiction risk profiles for patients before medical procedures.The science is compelling – addiction typically stems from a 50/50 split between genetic predisposition and behavioral factors. By analyzing both components through a proprietary algorithm, Thrive Genetics helps physicians tailor medication plans based on individual risk profiles. For high-risk patients, alternative approaches might include non-opioid medications or adjusted dosages, potentially saving countless individuals from developing dependencies.We explore the staggering statistics behind the opioid epidemic (Americans consume 99% of global hydrocodone) and discuss how personalized medicine represents a balanced approach that maintains quality care while addressing cost concerns. James walks us through the patient journey – from initial testing to personalized treatment plans – and shares powerful stories illustrating the human impact of addiction and recovery.Our conversation ventures beyond healthcare into profound territory, examining how family trauma shapes us, the nature of self-awareness in recovery, and philosophical questions about purpose and spiritual growth. James offers wisdom from both professional innovation and personal reflection, reminding us that sometimes our deepest wounds become the source of our greatest contributions to others.Connect with Thrive Genetics at thrivegeneticsai.com to learn more about this groundbreaking approach to addiction prevention and personalized medicine.http://www.thrivegenetics.ai/ Support the show https://www.audible.com/pd/9-Simple-Steps-to-Sell-More-ht-Audiobook/B0D4SJYD4Q?source_code=ASSORAP0511160006&share_location=library_overflowhttps://www.amazon.com/Simple-Steps-Sell-More-Stereotypes-ebook/dp/B0BRNSFYG6/ref=sr_1_1?crid=1OSB7HX6FQMHS&keywords=corey+berrier&qid=1674232549&sprefix=%2Caps%2C93&sr=8-1 https://www.linkedin.com/in/coreysalescoach/

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A breast cancer diagnosis can bring more than just emotional and physical challenges — it can also create a heavy financial burden. From the cost of treatment to lesser-known expenses like transportation, childcare and lost wages, the impact can be overwhelming. In this episode of Real Pink: Health Equity Revolution, we're joined by Toni Lee, Senior Manager of Susan G. Komen's Patient Care Center. Toni shares powerful insights about the real costs of breast cancer, how Komen supports patients financially — even when the Financial Assistance Program is closed — and how trained patient navigators can help individuals access the resources they need to reduce the burden. If you or someone you love is navigating breast cancer, this episode will leave you feeling seen, supported and empowered.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My guest is Dr. Sergiu Pașca, MD, professor of psychiatry and behavioral sciences at Stanford University. We discuss the biology and genetics of autism, why autism diagnoses are increasing and recent progress in using stem cells to understand and treat profound autism and other brain disorders. Dr. Pașca explains “organoids and assembloids”—human stem cell–derived tools he pioneered to study, treat and cure complex brain diseases. We also discuss ethical and safety issues with using gene editing and stem cells in humans. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Helix: https://helixsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00) Sergiu Pașca (02:08) Autism Spectrum Disorder, Incidence, Genetics (07:16) Is Autism More Common in Males? (09:35) Sponsors: David & Helix Sleep (11:56) Eye Contact in Babies, Fever; Proposed Causes of Autism; Genes (18:48) Genetic or Idiopathic Autism Diagnoses, Timothy Syndrome (21:37) Rise in Autism Diagnoses (26:46) Cause, Correlation & Neurological Disease; Schizophrenia, Do Vaccines Cause Autism? (31:34) Global Increase in Autism; Gene Therapy, CRISPR, Follistatin (41:05) Sponsors: AG1 & BetterHelp (43:41) Stem Cells, Ethics, Yamanaka Factors, Human Stem Cell Models (52:03) Umbilical Stem Cells; Stem Cell Injections & Dangers, Autistic Kids (59:30) Organoids, Modeling Brain Development, Intrinsic Development Timer (1:12:22) Assembloids, Brain Cell Migration & Circuit Formation, Self-Organization (1:21:22) Four-Part Assembloid, Sensory Assembloid, Pain Conditions (1:25:45) Sponsor: Function (1:27:33) Future Medical Therapies, Cell Banking, Immortalize Tissues, Rejuvenate Cells (1:34:56) Assembloids & Ethics, Importance of Nomenclature, Science Collaboration & Self-Correction (1:45:38) Cell Transplantation & Ethics, Timing (1:55:05) Genetic Testing for Parents, Genetic Penetrance (2:02:36) Assembloids, Timothy Syndrome, Epilepsy, Schizophrenia, Dystonia (2:14:30) Scientific Career, Walking, Art, Medical School (2:20:44) Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Donna Wentz is marking a remarkable milestone: 10 years of no evidence of breast cancer. Her journey began at just 39 years old, when she received the life-changing diagnosis of estrogen receptor-positive breast cancer. Faced with fear and uncertainty, Donna leaned on the unwavering support of her family, friends, and colleagues. Their encouragement carried her through the challenges of surgery, treatment, and recovery, helping her find strength she didn't know she had. Today, she reflects not only on surviving, but on the resilience, gratitude, and deeper connections that emerged from her experience.

Send comments and feedbackWhat are variants of uncertain significance (VUS) in epilepsy genetic testing? How are they defined, and can those definitions change over time? Sharp Waves talks with Dr. Gemma Carvill as part of our genetic testing series.RESOURCESStandards for interpreting variants (American College of Medical Genetics)Gene ReviewsClinVarGeneMatcherGnomadClinGenILAE genetic literacy seriesEpiPred website for STXBP1 (developed by EpiMVP project - will be final by end of July)Think Genetics paper – genetic testing in South Africa projectLink to Sharp Waves episode on genetic testing in LMICs  Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing: podcast@ilae.org.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.

In this compelling episode, host Melissa Berry continues the series "Decoding Destiny: Navigating Breast Cancer with Genetic Insight" with a heartfelt conversation with Krista Brown, also known on Instagram as the Cancer Prevention Coach. Krista, an oncology nurse navigator and breast cancer survivor, shares her journey of living with an ATM gene mutation and the empowering role of genetic testing in her life. Together, they explore the importance of education, nutrition, and self-advocacy in managing hereditary cancer risks. Tune in to discover how Krista's personal experiences have shaped her mission to fill gaps in patient education and support others on their cancer prevention journeys. Special thanks to AstraZeneca for making this episode possible.

How does genetic testing help doctors treat patients? How accurate are private companies like 23andMe? Does knowing your genetic risk help people lead healthier lives or is it just a waste of time and money? Sophie had a bunch of questions about how genetic testing is used in everyday medical practice and Chris was here to answer!   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: Studies evaluating the accuracy of Direct to Consumer genetic testing companies: Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature. 2009 Oct 8;461(7265):724-6. doi: 10.1038/461724a. PMID: 19812653. Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem. 2011 Mar;57(3):518-21. doi: 10.1373/clinchem.2010.158220.  Studies looking at how knowing the results of genetic testing affect medical treatment and lifestyle factors. Mega JL, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 6;385(9984):2264-2271. doi: 10.1016/S0140-6736(14)61730-X Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, Fuster V, Boerwinkle E, Melander O, Orho-Melander M, Ridker PM, Kathiresan S. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016 Dec 15;375(24):2349-2358. doi: 10.1056/NEJMoa1605086.  The Cochrane review and MI-GENES study which showed that genetic information did not change lifestyle behavior Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, Marteau TM. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016 Mar 15;352:i1102. doi: 10.1136/bmj.i1102.  Kullo IJ, et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation. 2016 Mar 22;133(12):1181-8. doi: 10.1161/CIRCULATIONAHA.115.020109  

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join the conversation as Matt and John talk about preseason football, genetic testing, and Marjorie Gestring.    0:00- intro 2:13- sports 14:45- genetic testing  40:50- today in sports 45:25- one thing  

Life changes in a split second when you hear the words, “you have breast cancer.” Shawna Bramel and Marian Santos know this personally. Shawna was diagnosed after having her first child, completely upending her family's plans for more children. Marian was diagnosed at a time when she should have been thinking about her future, planning a family and focusing on preserving her reproductive health. Both ladies struggled mentally, emotionally and physically with their diagnoses and are joining us today to share more.

Rachel Earls, Ph.D., outlines the roles, science, and limitations of this powerful clinical tool for the selection of medication. This is a great guide on how an individual metabolizes many medications, and so it helps get proper doses for better efficacy and fewer side effects. It does not predict outcome, but significantly assists with treatment choices. She also speaks to the differences between labs that require a medical prescription versus the direct to the consumer labs. This is a fascinating scientific utensil. July 2024

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For Dr. Priya, the autopsy is just the beginning. What happens next can change everything for the families left behind. In this episode, Dr. Priya Banerjee joins Sheryl McCollum, to examine a side of autopsies that rarely makes headlines: the profound responsibility of communicating with families. Dr. Priya reflects on the power of empathy in the autopsy suite, the deep importance of walking families through trauma with care, and the surprising ways postmortem findings can protect the living. She shares raw personal experiences—from the loss of her own parents to advocating for grieving families left behind during COVID—and the critical role of cultural awareness, front-line staff, and honest conversations. Listeners will also learn how autopsies sometimes uncover hereditary conditions that can lead to lifesaving interventions for surviving loved ones. This is forensic pathology not just as a science, but as a service. Highlights: (0:00) The emotional weight of entering the medical examiner’s office (1:30) Debunking the ‘grim reaper’ myth of pathology (3:00) Personal loss and professional insight: How Dr. Priya’s grief reshaped her work (5:45) The unsung heroes of the ME office—investigators and admin staff (6:45) Why Dr. Priya insists on calling families directly (9:00) Launching a private autopsy service in response to COVID-era needs (13:00) Managing expectations: What autopsies reveal and what they can’t (15:00) Working with families and finding closure (16:30) Cultural and religious barriers to autopsy (24:00) Why refusing an autopsy can hurt future legal or health outcomes (27:00) The hidden legacy of genetic disease (30:00) Dr. Priya’s pet and power of early intervention About the Hosts Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Her work includes military deaths, NSA cases, and high-profile investigations. Dr. Priya has also been featured as a forensic expert on platforms such as CrimeOnline and Crime Stories with Nancy Grace. She is a dedicated educator, animal lover, and proud mom. Website: anchorforensicpathology.comTwitter/X: @Autopsy_MD Sheryl McCollum is an Emmy Award–winning CSI, a writer for CrimeOnline, and the Forensic and Crime Scene Expert for Crime Stories with Nancy Grace. She works as a CSI for a metro Atlanta Police Department and is the co-author of the textbook Cold Case: Pathways to Justice. Sheryl is also the founder and director of the Cold Case Investigative Research Institute (CCIRI), a nationally recognized nonprofit that brings together universities, law enforcement, and experts to help solve unsolved homicides, missing persons cases, and kidnappings. Email: coldcase2004@gmail.comTwitter/X: @ColdCaseTipsFacebook: @sheryl.mccollumInstagram: @officialzone7podcast

You may have heard in the news that younger women are being diagnosed with breast cancer at higher rates than before. While women under 40 only account for 4% of breast cancer cases in the U.S., even a modest rise in breast cancer incidence is a call to action for young women to understand their personal risk and to know what's normal for their breasts so they can be aware of any changes that should be reported to a health care provider. Joining us on the show today is Dr. Virginia Borges, a medical oncologist at the University of Colorado, whose research focuses on young women's breast cancer. Dr. Borges is committed to finding answers and today will share what is being studied, as well as how young women can be empowered to take charge of their breast health early.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Tommy: Hello Stephen. I'm an IHP. A year ago I started having dhiarrea daily. My sleep also suffered, waking up in the night unable to fall back asleep even with magnesium/melatonin/breathwork. I had some leftover healthy belly, so began taking 2 morning and 2 night. Everything cleared up, my bowells were perfect , my mind was clearer, my body was calmer. I thought it was the mastic gum that had killed some h-pylori. About 7 days after stopping healthy belly, it all came back again. I've since done a parasite protocol which i had to stop 11 days before the end as I was feeling fatigued. I ran a stool test just before these symptoms and it showed citrabacter friundi. I'm unsure whether to do a parasite protocol again or run another stool test. Appreciate you                                                                                                                                             Tommy: Hello Stephen, I heard you mention that a certain percentage of folk (possibly with the APOE genotype if memory serves me correctly), experience more inflammation with a higher fat diet. Would it be worth running a generic test to refine my unique needs a bit more as I'm prone to inflammation? Obviously this comes after the basic big 5. And Would it also explain susceptibility to mycotoxins? Thankyou for all that you do             Kay: Hi Dr. Cabral, What would you recommend to 59 or 60 year olds who are a pitta/vata body type and tend to be more catabolic when it comes to your DCD? Would you recommend to modify the 2 fasting days? Both my husband and I are generally ok during Day 1 of the fast, but Day 2 is always so difficult - my husband got bad headaches and because he had to work and focus, he ended up prematurely ending the DCD. I have gotten nausea and chills on Day 2, but the most difficult part for me is just really wanting to eat solid food. It also seems that my muscle tone is weakened afterwards. I know that muscle goes away much quicker when you are over the age of 50. Thanks for all your great podcasts- they are always so informative and I look forward to your response!                                 Kay:  Hi Dr. Cabral- Thanks for your awesome podcasts and the opportunity for us to ask you questions. I'm a 59 year old female and am in menopause. I never had cellulite on my arms and back of my upper thighs and glutes until I began taking HRT. Currently, I am on 1mg oral bioidentical estradiol bid and 100 mg oral progesterone qd at bedtime. I also recently began taking 5 mg DHEA (equilife) bid. I am at a good weight (5'2" 110) and do strength training 3 x per week and walk an average of 10k steps per day. I also have recently incorporated your dry brushing techniques and plan to switch to topical HRT sometime this year with the help of my medical provider. I am wondering what else I can do to eliminate the cellulite?                                                                                                                                                                Shelley: Hello, Dr. Cabral! I have recently gone on a health and wellness journey, going from 228 lbs down to now 167 pounds in just over a year. To aid in the process, of course exercise was a part of it. With the exercise came all the injuries of olde, but mainly my knee. I injured it back in my college years playing tennis and surgery wasn't recommended as they wanted to see if it would heal itself (torn meniscus, mostly in the vascular area). Well, fast forward more years than I care to count, and that residual tear on the avascular portion can be problematic. I have been looking into peptides, specifically BPC-157 and TB-500 to potentially help this knee without surgical intervention. What are your thoughts on peptide use (these two in particular) and do you think they might help my knee?           Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3467 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.